With the ongoing rise in pollution, which is a major environmental risk to health, the need for upper respiratory relief is more prominent than ever. Utilizing Aptar Pharma’s well-established Bag-on-Valve system, PureHale’s innovative technology distributes a continuous fine mist (20-30µm) that gently cleanses, moisturizes and soothes the upper respiratory tract. When used in combination with a customer’s formulation, it could help to reduce irritations caused by coughs, colds, allergies, respiratory problems and dry nose/throat issues.
PureHale’s portability allows consumers to relieve their symptoms wherever and whenever needed. Unlike traditional nebulizers, the PureHale system does not require batteries or the prefilling of a reservoir and does not need to be plugged in or charged. The PureHale technology platform is quieter and lighter than traditional nebulizers, is easy-to-use and includes mask and mouthpiece options, offering adaptable treatment and suitable for family use.
Guenter Nadler, Director Business Development at Aptar Pharma said of this latest launch, “We are really excited to announce this newest Aptar Pharma innovation. We have seen a real need for a device of this kind – traditional nebulizers come with a set of challenges including complexities in setup, manual dexterity requirements and overall usage time. Meanwhile, challenges during medication administration include poor inhalation technique, duration of nebulization and understanding how to achieve optimal efficacy. PureHale has been designed specifically with these challenges in mind and offers a solution by simplifying the entire process.”
PureHale will be officially launched at CPhI Worldwide in Madrid on October 9th at Booth 4D10 and is a finalist in the CPhI Pharma Awards in the Excellence in Pharma: Drug Delivery Device category.
